摘要Background:BRCA1/2 mutations have been shown to be associated with the development of many solid tumors including endometrial cancer(EC).The objectives of this study are to analyze the association between BRCA1/2 mutational status and clinicopathological characteristics as well as outcomes in EC patients.Methods:510 eligible EC patients from the Cancer Genome Atlas database were included in the study.The as-sociation between clinicopathological characteristics and different BRCA1/2 mutational status was compared and analyzed.Analyses of the impact of BRCA mutations on survival in EC patients was conducted using Kaplan-Meier survival analyses and Cox regressions.In order to control confounding bias between groups,propensity score matching method was used.Results:Among the eligible patients,11(2.2％)harbored BRCA1 mutation,43(8.4％)harbored BRCA2 mutation,and 36(7.1％)harbored both.Body mass index,rates of hypertension history,proportion of non-endometrioid histology and rates of positive peritoneal cytology were lower in patients with BRCA1/2 mutations compared with the group of wild-type counterpart(p=0.020,0.048,0.001 and 0.012,respectively).Patients with BRCA1/2 mutations showed longer overall(OS)and recurrence-free survival(RFS)(in Kaplan-Meier analyses,p＜0.001 and p=0.004,respectively;in Cox regressions,p=0.001 and 0.007,respectively).Further analyses showed that the impact of BRCA mutations on survival was significant only in patients with high-grade endometrioid EC.Based on the cohorts generated after propensity score matching,in high-grade endometrioid EC patients,the influence of BRCA1/2 mutations remained significant on OS,but not on RFS(p=0.003 and 0.057 in Kaplan-Meier analyses,p=0.020 and 0.071 in Cox regressions).Conclusion:BRCA1/2 mutations are associated with better survival in patients with high grade endometrioid EC,indicating the value of BRCA testing in EC clinical management.